Gemcitabine plus radiotherapy for non-small cell lung cancer.

Radiosensitization promises to improve local control in patients with locally advanced non-small cell lung cancer (NSCLC). The nucleoside analogue gemcitabine, which is not only a potent radiosensitizer but also has significant antitumor activity in this disease, is an important candidate for such a strategy. This report describes the design of a clinical… (More)